FMO5 and diabetes mellitus: Since angiotensin II can activate NADPH oxidase to increase oxidative stress through the AT1 receptor [116, 117], the administration of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) is currently the regular treatment for diabetes with cardiovascular complications.